166 related articles for article (PubMed ID: 38584592)
1. Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA.
Wang J; Zhu L; Zhang S; Zhang Z; Fan T; Cao F; Xiong Y; Pan Y; Li Y; Jiang C; Yin S; Tong X; Xiong Y; Xia J; Yan X; Liu Y; Liu X; Chen Y; Li J; Zhu C; Wu C; Huang R
Emerg Microbes Infect; 2024 Dec; 13(1):2339944. PubMed ID: 38584592
[TBL] [Abstract][Full Text] [Related]
2. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J; Sun X; Fang J; Wang C; Han G; Ren W
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
[TBL] [Abstract][Full Text] [Related]
3. Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase.
Chen L; Shi J; Lu Z; Ye Y; Zhou X; Tan Y
Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):310-316. PubMed ID: 30528063
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
Coffin CS; Haylock-Jacobs S; Doucette K; Ramji A; Ko HH; Wong DK; Elkhashab M; Bailey R; Uhanova J; Minuk G; Tsoi K; Wong A; Ma MM; Tam E; Brahmania M; Nudo C; Zhu J; Lowe CF; Osiowy C; Lethebe BC; Congly SE; Chan EKH; Villasis-Keever A; Sbarigia U; Cooper CL; Fung S
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560672
[TBL] [Abstract][Full Text] [Related]
5. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
6. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
[TBL] [Abstract][Full Text] [Related]
7. [Analysis and significance of HBV DNA below the lower detection limit of HBV RNA levels after long-term NAs antiviral therapy in patients with hepatitis B virus cirrhosis].
Wang CY; Cao Y; Feng YM; Li J; Jiang B; Zhang Y; Wen J; Zhu YJ; Li J
Zhonghua Gan Zang Bing Za Zhi; 2022 Jul; 30(7):758-762. PubMed ID: 36038347
[No Abstract] [Full Text] [Related]
8. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between hepatitis B surface antigen, HBV DNA quantity and liver fibrosis severity].
Gao Y; Zou G; Ye J; Pan G; Rao J; Li F; Wei Y; Li X
Zhonghua Gan Zang Bing Za Zhi; 2015 Apr; 23(4):254-7. PubMed ID: 26133815
[TBL] [Abstract][Full Text] [Related]
10. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
11. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.
Zhang C; Yang Z; Wang Z; Dou X; Sheng Q; Li Y; Han C; Ding Y
Int J Med Sci; 2020; 17(3):383-389. PubMed ID: 32132873
[No Abstract] [Full Text] [Related]
12. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
13. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
[TBL] [Abstract][Full Text] [Related]
14. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
[TBL] [Abstract][Full Text] [Related]
16. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase.
Zhao Q; Liu K; Zhu X; Yan L; Ding Y; Xu Y; Lou S; Zhao G; Xie Q; Gao Y; Bao S; Wang H
Antiviral Res; 2020 Dec; 184():104953. PubMed ID: 33065138
[TBL] [Abstract][Full Text] [Related]
17. [A retrospective study on HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B aged 1-7 years].
Zhu SS; Dong Y; Xu ZQ; Wang LM; Chen DW; Gan Y; Wang FC; Yan JG; Cao LL; Wang P; Zhang HF
Zhonghua Gan Zang Bing Za Zhi; 2016 Oct; 24(10):738-743. PubMed ID: 27938558
[No Abstract] [Full Text] [Related]
18. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
[No Abstract] [Full Text] [Related]
19. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
[TBL] [Abstract][Full Text] [Related]
20. Large spontaneous HBV DNA fluctuations and potential usefulness of a single-point measurement of combined HBV DNA and quantitative HBsAg for the exclusion of HBeAg-negative chronic hepatitis B: A prospective Tunisian cohort study.
Chtourou A; Gargouri S; Elleuch E; Feki L; Smaoui F; Taktak A; Mnif K; Kassis M; Hammami A; Ben Jemaa M; Karray H
Arab J Gastroenterol; 2023 Nov; 24(4):223-229. PubMed ID: 37989673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
